From puberty to menopause — 30+ symptom tracking, on-device ML pattern detection, and clinical-grade cycle reports for your doctor.
Owns "track" positioning, signals premium ("Pro"), gender-inclusive modifier ("Fem"). Avoids "cycle" (generic), "period" (dated), or mystical names. "Pro" signals clinical sophistication vs. consumer simplicity.
Tagline: "AI Hormonal Health Companion — From Puberty to Menopause"
| Name | .com | .app | App Store Clear? | Trademark Risk | Score |
|---|---|---|---|---|---|
| FemTrack Pro | Available ($11.25/yr) | N/A | Clear | Low | 9/10 |
| Hormona Pro | Unverified | Unverified | Clear | Medium | 7/10 |
| CycleIQ | Unverified | Unverified | Clear | Low | 7/10 |
| HerFlow | Unverified | Unverified | Potential conflict | Medium | 6/10 |
| Vitality | Likely taken | Likely taken | Brand risk | High | 4/10 |
| Domain | Status | Price | Recommendation |
|---|---|---|---|
| femtrackpro.com | Available | $11.25/yr | PRIMARY CHOICE — Direct, branded, owns main keyword |
| femtracker.app | Available | $14.99/yr | Secondary option, modern TLD |
| hormonehealth.app | Available | $14.99/yr | Tertiary, broader positioning |
| cyclesense.app | Unavailable | — | Not available |
| femtrack.app | Unavailable | — | Not available |
FemTrack Pro targets the intersection of two high-growth femtech segments: advanced hormonal health tracking and menopause management. The app combines 30+ symptom tracking with on-device ML pattern detection and generates clinical-grade cycle reports — features that competitors Flo and Clue offer only partially. The menopause mode targets the underserved 40+ demographic. North America leads with 38.1% menstrual health app market share.
Smartphone penetration (68.32% of market), AI/ML adoption for personalized predictions, employer-sponsored menopause benefits expanding TAM, post-Roe privacy consciousness driving demand for privacy-first apps, and growing clinical integration demand for doctor-friendly reports and telehealth connectivity.
| Year | Downloads | Paid Users | Conversion | Annual Revenue |
|---|---|---|---|---|
| Year 1 | 100,000 | 5,000 | 5% | $399,950 |
| Year 2 | 500,000 | 40,000 | 8% | $3,199,600 |
| Year 3 | 1,500,000 | 180,000 | 12% | $14,397,800 |
Conservative estimates at $79.99/year ARPU. Menopause mode and clinical plan could add 20-30% upside. B2B partnerships (employers, telehealth) could add $500K-$2M annually by Y3.
Monetization model, marketing strategy, and the #1 complaint from users for each.
Largest user base, 70+ symptom tracking, AI health assistant, pregnancy mode, community features
Free tier; Premium $50/year. Aggressive premium upsell.
Privacy breaches (FTC 2021, Meta 2025, $56M settlement). User data sharing scandals. Cluttered interface with ads.
GDPR compliant, never sells data, science-backed predictions, password protection, CE Mark certified
Free tier; Clue Plus ~$39.99/year.
Limited wearable integration (users request more). No menopause mode. Smaller community feature set.
Only FDA-cleared app for contraceptive use. Strong TTC demographic. Highly accurate predictions.
$12.99/month. Higher price point than Flo/Clue.
Narrow use case focus. Not positioned for general hormonal health or menopause.
Founded by menopause specialist Dr. Louise Newson. Strong menopause symptom tracking. Apple recognition.
Premium pricing (higher than Flo). Menopause-specific.
Narrowly focused on menopause only (no period tracking for younger women). Smaller user base. Limited feature set.
ORCHA #1 ranked. Free model. Expert advice and guided exercises for perimenopause/menopause.
Free alternative. Limited feature depth and brand awareness.
Limited feature depth. Lower brand awareness. Less sophisticated than Balance.
No competitor combines on-device ML pattern detection, clinical-grade cycle reports for doctors, native menopause mode, and deep wearable integration. Flo has privacy damage. Clue lacks menopause and wearable depth. Balance can't serve the full hormonal lifecycle. FemTrack Pro owns all four pillars.
| Feature | FemTrack Pro | Flo | Clue | Balance | Natural Cycles |
|---|---|---|---|---|---|
| 30+ Symptom Tracking | Full | 70+ (excess) | Selective | Menopause focused | Limited |
| On-Device ML | Core Feature | Cloud-based | Cloud-based | Basic | Limited |
| Clinical Cycle Reports | Built-in | Symptom checker only | No | No | No |
| Menopause Mode (40+) | Native | No | No | Primary focus | No |
| HealthKit Integration | Deep | Limited | Limited | Basic | Limited |
| Privacy (No data sales) | Yes | Improved but history | GDPR | Yes | Unclear |
| Wearable Sync | Oura, Watch, Fitbit | Apple Watch only | Multiple | Limited | Limited |
| Age Range Focus | 15-55+ | 15-50 | 15-50 | 40-65 | 18-45 |
| App | Focus | Notes |
|---|---|---|
| Stardust | Astrological angle | End-to-end encryption, niche community appeal |
| Glow | Fertility & TTC | Community-driven, 40+ health signals tracking |
| Ovia | Fertility emphasis | Daily fertility scores, employer-sponsored plans |
| mySysters | Perimenopause/menopause | Discussion forums, small user base |
| Midday | Menopause-specific | Science-backed, AI + wearable sensing |
| Element | Recommended Copy | Char Count |
|---|---|---|
| App Store Title | FemTrack Pro: Hormone Health | 30/30 |
| Subtitle | AI-Powered Hormonal Health Tracking for Every Life Stage | 55/30* |
| Primary Category | Health & Fitness | — |
| Keywords | hormonal health, menopause, period tracker, cycle tracking, fertility, symptom tracking, women's health, AI, wearable, HealthKit | — |
High market fit, defensible differentiation, proven business model, significant TAM ($7.52B menstrual + $345M menopause + $12.87B broader women's health), clear competitive advantage via on-device ML, clinical reporting, and native menopause mode. Flo's privacy damage and Clue's feature gaps create real opening. Timing is optimal: menopause market on inflection, privacy consciousness at peak. Go forward with execution.
| Biggest Risk | Biggest Opportunity |
|---|---|
| Flo's market dominance (420M downloads, 67M MAU). Network effects, app store prominence, and first-mover inertia create high user acquisition cost barrier. | Privacy-first positioning + clinical reports + menopause mode fills documented gaps no competitor currently covers. Flo's $56M privacy settlement creates real opening for trust-first alternative. |
| Risk | Mitigation |
|---|---|
| Privacy regulation uncertainty (GDPR, state-level laws) | Over-build privacy from day 1. SOC 2 Type II, HIPAA eligibility, GDPR/CCPA compliance. |
| Menopause market fragmentation (Balance, Elektra, Gennev) | Position as "full hormonal lifecycle" (periods to menopause). Cross-sell retention advantage. |
| Clinical credibility barrier for doctor reports | Pursue CE Mark within 18 months. OB/GYN advisory board. Peer-reviewed validation study. |
| Wearable API dependency (HealthKit, Oura, Fitbit) | Primary HealthKit integration. Build in-app sensor alternatives (HRV from iPhone camera). |
| Data monetization pressure from investors | Benefit corporation structure. Revenue = subscriptions + B2B, NOT data sales. |
Bundle ID and IAP product IDs must be created in App Store Connect first. Mismatches are the #1 cause of upload failures.
com.dreamseeds.femtrackproRegister in Apple Developer Portal → Certificates, IDs & Profiles → Identifiers
Free tier: basic tracking (5-10 symptoms), 6-month history. Premium $9.99/mo or $79.99/yr. Clinical Plan $19.99/mo or $179.99/yr.
Period trackers, fertility seekers, perimenopause/menopause women. Privacy-conscious users leaving Flo. Healthcare-seeking users wanting clinical reports.
| # | Feature | Why It Matters | Session |
|---|---|---|---|
| 1 | 30+ Symptom Tracking | Mood, energy, skin, digestion, sleep — integrated into unified hormonal health view beyond basic calendar. | S2 |
| 2 | On-Device ML Pattern Detection | Local ML for privacy + speed. Discovers patterns like "3-day mood dips 7 days before period." No cloud dependency. | S3 |
| 3 | Clinical Cycle Reports (PDF) | Generate doctor-ready reports with symptoms, cycle length trends, pattern summaries. Unique feature no competitor has. | S4 |
| 4 | HealthKit + Wearable Sync | Seamless Oura + Apple Watch + Fitbit sync. Auto-populates sleep, HRV, exercise. Reduces manual entry friction. | S5 |
| 5 | Menopause Mode | HRT tracking, hot flash logging, bone health alerts. Targets underserved 40-65 demographic ($345.6M TAM). | S6 |
| 6 | Cycle Syncing Guide | Workout/nutrition recommendations aligned with cycle phases. Content/UX opportunity competitors miss entirely. | S7 |
| 7 | Privacy-First Architecture | No data sales, no third-party sharing, transparent policy. Clear messaging advantage vs. Flo's reputation damage. | S1 |
| Phase | Timeline | Activities |
|---|---|---|
| Phase 1 | Months 1-4 | Waitlist via landing page. Reddit/TikTok/Instagram campaigns. 5-10 women's health influencer partnerships. SEO blog content. |
| Phase 2 | Month 5 | iOS beta via TestFlight to 5K-10K waitlist users. Feedback loops. User testimonials. |
| Phase 3 | Month 6 | iOS + Android launch. App Store featuring campaign. Paid UA on TikTok/Instagram. PR push. |
| Phase 4 | Months 7-12 | B2B partnerships (Ro, Nurx, Maven). Community building. Wearable partnerships. Target CAC $3-5, LTV $80-120. |